NovaMedica is in advanced negotiations to secure Russia and CIS rights for a wide range of innovative Products. We are seeking specialty pharmaceutical drugs and devices from various potential US and European partners (including Domain Associates, Inc. portfolio companies) spanning several high-growth therapeutic areas in hospital inpatient, hospital outpatient and specialty care clinical contexts. Products can be both FDA/EMA approved and phase 2B/3 late-stage development. Please check back regularly as we grow our pipeline to serve this exciting market.
NovaMedica to localize in Russia one of the most popular anti-migraine drugs in the world
21 March 2023
Merry Christmas and Happy New Year!
27 December 2022
15 December 2022
4 Key Priorities for the European Medicines Agency in 2023
02 June 2023
CRISPR-based microbial gene therapy delivers promise
02 June 2023
FDA Releases Final Guidance on Adjusting for Covariates in Randomized Clinical Trials
01 June 2023
Small biotech turns CRISPR against bacteria, reducing E. coli in small early study
01 June 2023